Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Purchased by American Century Companies Inc.

American Century Companies Inc. raised its position in Cytokinetics, Incorporated (NASDAQ:CYTK) by 8.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 356,576 shares of the biopharmaceutical company’s stock after buying an additional 27,619 shares during the period. American Century Companies Inc.’s holdings in Cytokinetics were worth $16,773,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Jones Financial Companies Lllp lifted its position in shares of Cytokinetics by 189.8% in the fourth quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 374 shares in the last quarter. Centricity Wealth Management LLC purchased a new position in Cytokinetics in the 4th quarter valued at $29,000. AlphaQuest LLC boosted its stake in Cytokinetics by 113,500.0% during the 4th quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 1,135 shares during the last quarter. J.Safra Asset Management Corp grew its holdings in shares of Cytokinetics by 62.1% during the fourth quarter. J.Safra Asset Management Corp now owns 1,751 shares of the biopharmaceutical company’s stock worth $83,000 after buying an additional 671 shares in the last quarter. Finally, Blue Trust Inc. grew its holdings in shares of Cytokinetics by 85.8% during the fourth quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 842 shares in the last quarter.

Cytokinetics Stock Down 6.9 %

Cytokinetics stock opened at $40.19 on Tuesday. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28. The firm has a 50 day moving average price of $45.64 and a 200 day moving average price of $49.42. Cytokinetics, Incorporated has a fifty-two week low of $39.81 and a fifty-two week high of $75.71. The company has a market capitalization of $4.76 billion, a PE ratio of -7.47 and a beta of 0.95.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.29) by $0.03. The firm had revenue of $16.93 million during the quarter, compared to analysts’ expectations of $14.26 million. Research analysts expect that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Andrew Callos sold 3,341 shares of the company’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $43.27, for a total transaction of $144,565.07. Following the sale, the executive vice president now owns 64,434 shares of the company’s stock, valued at approximately $2,788,059.18. This represents a 4.93 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Robert I. Blum sold 15,000 shares of the stock in a transaction on Monday, March 31st. The shares were sold at an average price of $40.75, for a total value of $611,250.00. Following the completion of the sale, the chief executive officer now owns 427,629 shares in the company, valued at approximately $17,425,881.75. The trade was a 3.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 58,834 shares of company stock worth $2,560,525 over the last three months. Company insiders own 3.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Stifel Nicolaus started coverage on shares of Cytokinetics in a research report on Wednesday, January 22nd. They set a “buy” rating and a $80.00 price target on the stock. Citigroup started coverage on Cytokinetics in a report on Friday, February 7th. They set a “buy” rating and a $86.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $120.00 price target on shares of Cytokinetics in a report on Friday, February 28th. Needham & Company LLC reissued a “buy” rating and set a $72.00 price objective on shares of Cytokinetics in a research note on Thursday, February 6th. Finally, JMP Securities restated a “market outperform” rating and issued a $78.00 target price on shares of Cytokinetics in a report on Friday, February 7th. Two analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Cytokinetics presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.00.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.